Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 9,880 | 17,898 | -85,480 | 4,314 | -87,933 |
| Depreciation Amortization | 2,520 | 1,588 | 1,114 | 1,129 | 290 |
| Income taxes - deferred | -1,109 | -1,002 | -1,160 | -838 | N/A |
| Accounts receivable | -10,806 | -5,257 | 285 | -7,920 | 1,495 |
| Accounts payable and accrued liabilities | 13 | -245 | 192 | -112 | 500 |
| Other Working Capital | -15,554 | -15,688 | 7,458 | -7,797 | 483 |
| Other Operating Activity | 16,066 | -935 | 103,483 | 21,901 | 1,410 |
| Operating Cash Flow | $1,010 | $-3,641 | $25,892 | $10,677 | $-83,755 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -1,686 | -1,000 | -1,332 | N/A |
| PPE Investments | -1,160 | -1,914 | -7,853 | -4,985 | -839 |
| Net Acquisitions | N/A | N/A | -124 | N/A | N/A |
| Purchase Of Investment | -14,010 | -15,471 | -15,735 | -7,484 | N/A |
| Sale Of Investment | 15,429 | N/A | N/A | N/A | 49,028 |
| Purchase Sale Intangibles | -733 | -813 | -69 | -13 | N/A |
| Other Investing Activity | -733 | -813 | 4,952 | -13 | 0 |
| Investing Cash Flow | $-474 | $-19,884 | $-19,760 | $-13,814 | $48,189 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 25,865 | 2,638 | N/A | N/A | 49,553 |
| Other Financing Activity | -1,487 | -536 | 2,500 | 0 | 0 |
| Financing Cash Flow | $24,378 | $2,102 | $2,500 | $N/A | $49,553 |
| Exchange Rate Effect | 343 | -273 | -298 | -1,891 | N/A |
| Beginning Cash Position | 11,813 | 33,509 | 25,175 | 30,203 | 30,360 |
| End Cash Position | 37,070 | 11,813 | 33,509 | 25,175 | 44,347 |
| Net Cash Flow | $25,257 | $-21,696 | $8,334 | $-5,028 | $13,987 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,010 | -3,641 | 25,892 | 10,677 | -83,755 |
| Capital Expenditure | -1,190 | -2,315 | -8,517 | -4,985 | -839 |
| Free Cash Flow | -180 | -5,956 | 17,375 | 5,692 | -84,594 |